

## References

I-55

1. Germain DP, Charrow J, Desnick RJ et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. *J Med Genet.* 2015;52:353-358.
2. Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. *J Am Soc Nephrol.* 2013;24(1):137-48.
3. Desnick RJ. Genetics of Fabry Disease Treatment and Management. Medscape. Last updated Feb 24, 2016.
4. Fabrazyme® [package insert]. Cambridge, MA: Genzyme Corp. 2017.
5. U.S. Food and Drug Administration (FDA), Fabrazyme®. Published 2003
6. Gold Standard, Inc. Agalsidase Beta. Clinical Pharmacy [database online]. Revised 4/7/2015.
7. Wijburg F, Bénichou B, Ramaswami U, et al. Characterization of early disease status in treatment-naïve male paediatric patients with Fabry disease enrolled in a randomized clinical trial. *Plos One.* 2015;10(5):e0124987.
8. Mehta A, Hughes DA. Fabry Disease. 2002 [Updated 2017 Jan 5]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle;1993-2017.
9. Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. *Journal of Inherited Metabolic Disease.* 2011;34(2):509-514.
10. Cousins A, Lee P, Rorman D, et al. Home-based infusion therapy for patients with Fabry disease. *Brit J Nurs.* 2008;653-657.
11. Fabrazyme® (agalsidase beta) Home Infusion Therapy: A guide for healthcare professionals treating patients with fabry disease. Cambridge, MA. Genzyme Inc; 2015.
12. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare.* 2016.
13. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
14. MICROMEDEX® SOLUTIONS Compendia. 2017. AGALSIDASE BETA.
15. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Agalsidase Beta.